记者金音,见习记者彭康一 据投资快报梳理统计，上周（8月11日至8月17日）A股市场共有124家上市公司披露股东减持计划，合 计拟套现金额达到167.28亿元。此次减持涉及计算机、通信和其他电子设备制造业、专用设备制造业、 电气机械和器材制造业等37个行业，既有控股股东、高管等内部人士，也包括私募股权基金、产业投资 机构等外部股东。若按公告日收盘价计算，此次拟减持的金额区间跨度较大，最高拟减持金额达到9.41 亿元，最低拟减持金额为4.43万元。 进一步分析减持比例，计划减持比例达到3%及以上的企业有28家，涉及金额达58.68亿元，占总金额的 35.08%；计划减持比例在1%～3%（不含3%）之间的企业有52家，涉及金额达到97.07亿元，占总金额 的58.03%；计划减持比例在1%以下的企业达到44家，涉及金额仅为11.53亿元，占总金额的6.89%。 根据同花顺iFinD数据，上周发布减持计划的124家公司分布于37个证监会(新)一级行业，其中计算机、 通信和其他电子设备制造业（24家）、专用设备制造业（13家）、软件和信息技术服务业（12家）位居 减持企业数量前三，合计占比达39.52%。若按计划减持 ...

Group 1 - The core stock price of Xiangsheng Medical (688358) closed at 33.25 yuan on August 15, 2025, down 1.77% with a turnover rate of 3.63% and a trading volume of 40,700 shares, resulting in a transaction amount of 133 million yuan [1] - On August 15, the net outflow of main funds was 16.81 million yuan, accounting for 12.62% of the total transaction amount, while retail investors had a net inflow of 16.88 million yuan, accounting for 12.67% of the total transaction amount [4] - The company announced that its actual controller, chairman, and senior management personnel, Mo Ruoli, plan to reduce their holdings by no more than 3,363,735 shares, which is 3.00% of the total share capital, within three months starting from 15 trading days after the announcement [3][4] Group 2 - The company does not currently engage in research related to brain-machine interface technology, despite investor inquiries about its potential development [2] - The company has utilized NVIDIA chips in some of its products and is actively seeking technology partners to promote the development of ultrasound artificial intelligence technology [2]

Group 1 - The global robotics industry is experiencing explosive growth, with the healthcare sector becoming a key battleground for technological integration [1] - Xiangsheng Medical has launched the "Breast Artificial Intelligence Ultrasound Robot" system, addressing the screening challenges of breast cancer, the most prevalent cancer globally [2] - The new system integrates ultrasound, robotics, and artificial intelligence, enabling large-scale patient scanning and data management [2] Group 2 - Xiangsheng Medical has developed 61 core technologies, including harmonic imaging and high-speed blood flow detection systems, demonstrating its deep technological accumulation over nearly 30 years [2] - The company’s products have received international certifications such as EU CE and US FDA, indicating its research and development level is at the international advanced level [2] - The company has established strategic partnerships with several international medical giants through an ODM model, contributing to its revenue [2] Group 3 - Xiangsheng Medical is pioneering the ultrasound AI diagnostic field in China, creating a complete value chain of "precise screening - intelligent diagnosis - personalized rehabilitation" [3] - The company employs a dual-engine approach of "ultrasound artificial intelligence + specialized models" to build a technological moat [3] - The ultrasound imaging equipment market in China is projected to grow from 10.4 billion yuan in 2021 to 17.1 billion yuan by 2026, with a compound annual growth rate of 10.5% [3]

截至2025年8月15日收盘，祥生医疗（688358）报收于33.25元，较上周的33.64元下跌1.16%。本周，祥 生医疗8月12日盘中最高价报35.73元。8月15日盘中最低价报32.03元。祥生医疗当前最新总市值37.28亿 元，在医疗器械板块市值排名100/126，在两市A股市值排名4001/5152。 公司公告汇总 祥生医疗股东减持股份计划公告显示，实际控制人、董事长及高级管理人员莫若理女士直接持有公司股 份26,460,000股，占公司总股本的23.60%，均为无限售流通股。莫若理女士计划在公告披露之日起15个 交易日后的3个月内，通过集中竞价或大宗交易的方式减持合计不超过所持公司股份3,363,735股，即不 超过祥生医疗总股本的3.00%。其中以集中竞价方式拟减持股份数量为合计不超过1,121,245股，即不超 过祥生医疗总股本的1.00%；以大宗交易方式拟减持股份数量为合计不超过2,242,490股，即不超过祥生 医疗总股本的2.00%。减持原因为股东自身资金需求及资金规划。本次减持计划不会对公司治理结构、 股权结构及持续经营产生影响。在减持期间，股东将根据市场情况、公司股价等因素决定是否 ...

Group 1 - The stock price of Xiangsheng Medical is 33.25 yuan, down 0.60 yuan or 1.77% from the previous trading day [1] - The opening price was 33.06 yuan, with a high of 33.40 yuan and a low of 32.03 yuan, and the trading volume reached 40,700 lots with a transaction value of 133 million yuan [1] - Xiangsheng Medical operates in the medical device industry, focusing on the research, manufacturing, and sales of ultrasound medical imaging equipment, with 99.88% of its revenue in 2024 coming from this sector [1] Group 2 - On August 14, the company announced that its actual controller, Mo Ruoli, plans to reduce his holdings by up to 3% of the total share capital, which amounts to 3.36 million shares, between September 5 and December 4, 2025 [1] - Mo Ruoli currently holds 23.6% of the company's shares, with plans to reduce up to 1.12 million shares through centralized bidding and 2.24 million shares through block trading [1] - On the same day, the net outflow of main funds was 16.81 million yuan, accounting for 0.45% of the circulating market value, with a cumulative net outflow of 18.32 million yuan over the past five trading days, representing 0.49% of the circulating market value [1]

Core Viewpoint - The announcement of a share reduction plan by Xiangsheng Medical's shareholder, Mo Ruoli, indicates a potential shift in shareholding dynamics, although it is stated that this will not affect the company's governance structure or control [1][2]. Group 1: Share Reduction Plan - Mo Ruoli plans to reduce holdings by up to 3,363,735 shares, representing 3.00% of the total share capital of Xiangsheng Medical, within three months after the announcement [1]. - The reduction will occur through two methods: a maximum of 1,121,245 shares (1.00% of total shares) via centralized bidding and up to 2,242,490 shares (2.00% of total shares) through block trading [1]. Group 2: Shareholder Information - Mo Ruoli holds 26,460,000 shares, accounting for 23.60% of the total share capital, all of which are tradable shares obtained prior to the company's IPO and through capital reserve conversion [1][2]. - Mo Ruoli is the chairman and general manager of the company and is part of a concerted action group that collectively holds 54,263,956 shares, or 48.41% of the total share capital [2]. Group 3: Company Financials - Xiangsheng Medical raised a total of 1,010.60 million yuan from its IPO, with a net amount of 919.49 million yuan after deducting issuance costs, which were 91.10 million yuan [3]. - The net fundraising amount was 33.94 million yuan less than the original plan of 953.44 million yuan, which was intended for projects related to ultrasound medical imaging equipment and operational base construction [3].

祥生医疗(688358.SH)今日早盘一度跌5.38%至32.03元。祥生医疗公告称，实际控制人、董事长及高级管理人员莫若理拟自本减持计划公告披露之日起15个 交易日后的3个月内，通过集中竞价或大宗交易的方式减持合计不超过所持公司股份3,363,735股，即不超过祥生医疗总股本的3%。(格隆汇) ...

祥生医疗(688358.SH)公告，公司实际控制人、董事长及高级管理人员莫若理拟自本减持计划公告披露 之日起15个交易日后的3个月内，通过集中竞价或大宗交易的方式减持合计不超过所持公司股份336.37 万股，即不超过祥生医疗总股本的3.00%。 ...

智通财经APP讯，祥生医疗(688358.SH)公告，公司实际控制人、董事长及高级管理人员莫若理拟自本 减持计划公告披露之日起15个交易日后的3个月内，通过集中竞价或大宗交易的方式减持合计不超过所 持公司股份336.37万股，即不超过祥生医疗总股本的3.00%。 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-019 无锡祥生医疗科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 大股东及董监高持有的基本情况 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份，涉及公司首次公开发行前取得的股份已于 ? 减持计划的主要内容 因股东自身资金需求及资金规划，公司股东莫若理女士拟自本减持计划公告 披露之日起 15 个交易日后的 3 个月内，通过集中竞价或大宗交易的方式减持合 计不超过所持公司股份 3,363,735 股，即不超过祥生医疗总股本的 3.00%。其中 以集中竞价方式拟减持股份数量为合计不超过 1,121,245 股，即不超过祥生医疗 总股本的 1.00%；以大宗交易方式拟减持股份数量为合计不超过 2,242,490 股， 即不超过祥生医疗总股本的 2.00%。 一、减持主体的基本情况 | 股东名称 | 莫若理 | | | | | --- | -- ...